Lakewood-Amedex gets notice of allowance from USPTO for new patent covering nanoRNA gene-silencing technology

Paul DiTullio, Vice President, Product Development remarked, "The major advantages of the Company’s nanoRNA technology over other antisense, gene-silencing and RNAi technologies is a proprietary chemistry that overcomes the challenges of delivery.

"We have demonstrated in published studies that our compounds are highly effective when delivered intranasally against avian influenza and orally for the treatment of muscle wasting.

"This is a great advantage when treating chronic diseases such as inflammation, hepatitis, and cancer and also acute indications such as viral diseases. While our main focus is on the Bisphosphocin™ family of broad spectrum antimicrobials about to enter human clinical trials due to the recent spike in viral outbreaks of Ebola and enterovirus we are now accelerating development of our lead nanoRNA therapeutic, Influ-nRNA, as a treatment for all influenza viral strains including H5N1 and H1N1.

"Our aim is to validate this platform technology for the rapid development of therapeutics to treat emerging viral diseases such as Ebola, SARS, and MERS, particularly given the current epidemics. This approach of rapidly shutting down viral replication may have significant advantages over vaccines that typically have limited product life and need to be given prior to infection."

Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis, and a fully human monoclonal antibody for HUS.